Plain-English translation of NCT05904028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with wet age-related macular degeneration (a serious eye condition affecting vision) can have better outcomes by using a home optical coherence tomography device—a special scanner you use daily at home—to guide their treatment with faricimab injections. The study will compare this home-monitoring approach to the standard 'treat and extend' method, where patients come to the clinic regularly and injections are scheduled based on a set calendar.
Wet age-related macular degeneration requires frequent injections to prevent vision loss, but doctors currently don't know the best number of injections each person needs. Some patients get more injections than necessary, while others don't get enough. This medication is effective, but the current monitoring schedule (visiting the clinic every 1–2 months) may not catch all the changes in your eye. Daily home scans could allow doctors to personalize treatment better and potentially reduce the treatment burden and cost for patients.
If you join this study, you will receive intravitreal injections of the medication faricimab over 104 weeks (about 2 years). Depending on which group you're assigned to, you'll either use a home OCT scanner daily to monitor your eye and guide when you need injections, or follow the standard 'treat and extend' schedule where you visit the clinic regularly and injections are planned in advance. You'll start with a baseline injection and initial training on the home device (if assigned to that group), followed by regular clinic visits for eye exams and imaging. Commitment to the study includes being willing to perform daily monitoring without long trips away (more than 14 days) for the full 2-year period.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States